The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States.
about
A systematic review of modelling approaches in economic evaluations of health interventions for drug and alcohol problemsUse of pharmacotherapies in the treatment of alcohol use disorders and opioid dependence in primary careRetention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependenceCost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug usersCost-effectiveness of buprenorphine and naltrexone treatments for heroin dependence in MalaysiaCost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trialThe hepatitis C cascade of care: identifying priorities to improve clinical outcomesEstimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.Practical considerations for the clinical use of buprenorphine.Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASIThe impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsClinic variation in the cost-effectiveness of contingency managementCost-effectiveness of prize-based contingency management in methadone maintenance treatment programs.Longitudinal association of preference-weighted health-related quality of life measures and substance use disorder outcomesCost-effectiveness analysis of brief and expanded evidence-based risk reduction interventions for HIV-infected people who inject drugs in the United StatesOutpatient marijuana treatment for adolescents. Economic evaluation of a multisite field experiment.Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.Supply of buprenorphine waivered physicians: the influence of state policies.The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.Clinical impact of treatment timing for chronic hepatitis C infection: a decision modelCost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs.Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.A call for evidence-based medical treatment of opioid dependence in the United States and Canada.Costs of addressing heroin addiction in Malaysia and 32 comparable countries worldwide.Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11Cost-effectiveness analysis of four interventions for adolescents with a substance use disorderEvidenced-based treatment of opioid-dependent patients.The role of economics in the QUERI program: QUERI SeriesThe cost-effectiveness of four treatments for marijuana dependence.Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.The cost of providing methadone maintenance treatment in Ontario, Canada.Lessons From Medicaid's Divergent Paths On Mental Health And Addiction Services.Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients.Economic evaluation of continuing care interventions in the treatment of substance abuse: recommendations for future research.Preference-weighted health-related quality of life measures and substance use disorder severityCost-effectiveness analysis of Recovery Management Checkups (RMC) for adults with chronic substance use disorders: evidence from a 4-year randomized trialTreatment of co-occurring alcohol and other drug use disorders.Establishing the feasibility of measuring performance in use of addiction pharmacotherapy.A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence.
P2860
Q28072735-B1A57959-B806-4E94-B3F1-16BF6011DCF8Q28081029-6227D3B3-8206-46BA-9482-0E27A1715DADQ28265279-8AF0D3BD-3716-48BF-A4C4-90CDA8C0934CQ28483820-8BA928CC-1F99-495C-ADBF-9E7025903994Q28485456-9104E6F9-1D59-41A7-BDC2-6203F8D2E68BQ33631514-2335CFED-FE5F-4D51-85BB-CE60F9772BC3Q33632459-83301B26-A42B-41CF-B57B-35A83CB508C8Q33724701-7A0D846D-7D2A-4511-97BD-BC0F43BB4077Q33774853-7AF4DCC6-2F7F-494D-B08F-CA65ABD15572Q34520242-E4C3157B-7692-494C-892A-2F276DE66818Q34543555-DF9A378A-F770-4D75-BAC3-296A43011CE2Q34735072-80E19855-4352-4675-AD7C-1F40265BFA69Q34769497-48AE42DD-F375-4951-A919-33CF905ED749Q34773845-13FFA50E-2385-4F3E-B0EE-F58178049470Q34789105-C7D88738-E77B-458A-B077-92179C2685C1Q35058786-B6AB4760-00CB-4E23-AB30-3C5F9BEE4BD4Q35213184-3CDAED93-385A-485F-BBBD-7783B4A76F38Q35490468-D57E3565-2358-4102-91A6-85B4FE8E6781Q35571613-3CCFA0CF-E276-450E-9840-59B1C11C6052Q35572125-F144825E-371C-4B34-BDCB-9BFEBA55A093Q35889164-30CF91E3-D347-4E4A-B1FB-9FF7FB287B51Q35944736-FA6FB026-E7BA-4AA9-8F75-E4EB8AD688F7Q35980664-0FB1D115-F70B-43DB-9658-E64DC327F70DQ36062082-B019039A-548C-4336-9445-749F34196423Q36166640-58A73C84-7623-44B2-8F93-EC195143FE30Q36549928-2CF3FBFA-BE85-4DA5-B948-CF4FEA6E18F3Q36570531-16AF52B4-7243-4D44-82F1-201E12AF5136Q36628470-47117383-1E1F-4256-978A-D15ED45E490AQ36665721-AB6BCA0D-4B58-49E4-A6AE-172C00979972Q36681345-17F83068-197E-44DA-8460-63DD0772FFCFQ36711790-65A1FFAE-D232-4F42-86A1-1389DD2FE287Q36766215-208B2652-6782-4BCF-900D-C6C62EAB51FDQ36798074-C7ADAAC7-83B7-41CF-A277-69525155A752Q37105100-95A0E308-77FF-4B52-AEF1-C7BD040449C4Q37107739-9C83519E-974E-4AD9-B224-4721BCC66400Q37156802-5ED33A66-D0D1-48A0-AFA0-E800BC8B3440Q37325441-AF3CF04F-B618-4EBB-A1B5-EF9D3A438D10Q37386522-6BCB4EAE-4825-41F6-8533-2C68DAF2AAC3Q37638165-FDE2FB23-2C0C-419C-8F6E-3A8EAD914B1BQ37663311-9515F5CD-9FC9-4D3E-B51C-435EF99049F3
P2860
The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The cost-effectiveness of bupr ...... ddiction in the United States.
@ast
The cost-effectiveness of bupr ...... ddiction in the United States.
@en
The cost-effectiveness of bupr ...... ddiction in the United States.
@nl
type
label
The cost-effectiveness of bupr ...... ddiction in the United States.
@ast
The cost-effectiveness of bupr ...... ddiction in the United States.
@en
The cost-effectiveness of bupr ...... ddiction in the United States.
@nl
prefLabel
The cost-effectiveness of bupr ...... ddiction in the United States.
@ast
The cost-effectiveness of bupr ...... ddiction in the United States.
@en
The cost-effectiveness of bupr ...... ddiction in the United States.
@nl
P2093
P1433
P1476
The cost-effectiveness of bupr ...... ddiction in the United States.
@en
P2093
P304
P356
10.1046/J.1360-0443.2001.96912676.X
P407
P577
2001-09-01T00:00:00Z